Randomized phase II trial of deferasirox (Exjade•, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload

Haematologica

Volumn 91, Issue 7, 2006, Pages 873-880

  Piga, Antonio ^a   Galanello, Renzo ^b   Forni, Gian Luca ^c   Cappellini, Maria Domenica ^d   Origa, Raffaella ^b   Zappu, Antonietta ^b   Donato, Guido ^a   Bordone, Elena ^a   Lavagetto, Antonella ^c   Zanaboni, Laura ^d   Sechaud, Romain ^e   Hewson, Nicola ^e   Ford, John M ^e   Opitz, Herbert ^e   Albert, Daniele ^e  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Deferasirox; Deferoxamine; Efficacy; Iron chelation; Thalassemia; Well tolerated

Indexed keywords

DEFERASIROX; DEFEROXAMINE; DEFEROXAMINE MESYLATE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEMOSIDEROSIS; HUMAN; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THALASSEMIA;

ADOLESCENT; ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; BLOOD TRANSFUSION; DEFEROXAMINE; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIAZOLES;

EID: 33745774771     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998;850:227-31.
2. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee, A, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-8.
3. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
4. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95:26-36.
5. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051-2.
6. European Medicines Agency. Ferriprox European Public Assessment Report, Scientific Discussion. www.emea.eti.int 2005.
7. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-7.
8. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002;28:196-208.
9. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-23.
10. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects or deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-96.
11. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-7.
12. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-44.
13. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-4.
14. Athanassiou-Metaxa M, Kousi A, Hatzipantelis ES, Tsatra I, Ikonomou M, Perifanis V, et al. Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients. Haematologica 2004;89:ELT07.
15. Kattamis A. Combined therapy with deferoxamine and deferiprone. Ann N Y Acad Sci 2005;1054:175-82.
16. Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, et al. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematol J 2004;5:475-9.
17. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005;90:1309-14.
18. Heinz U, Hegetschweiler K, Acklin P, Faller B, Lattmann R, Schnebli HP. 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid: a novel, efficient and selective iron(iii) complexing agent. Angew Chem Int Ed Engl 1999;38:2568-70.
19. Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003;10:1065-76.
20. Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, et al. ICL670A: preclinical profile. Adv Exp Med Biol 2002;509:185-203.
21. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol 2003;43:565-72.
22. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-602.
23. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343:327-31.
24. Brittenham GM, Farrell DE, Harris JW, Feldman ES, Danish EH, Muir WA, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982;307:1671-5.
25. Brittenham GM, Badman DG. Non-invasive measurement of iron: report of an NIDDK workshop. Blood 2003;101:15-9.
26. Fischer R, Engelhardt R, Gabbe EE, Heinrich HC, Schmiegel WH, Wurbs D. Liver iron quantification in the diagnosis and therapeutic control of iron loaded patients. In: Hoke M, Erne SN, Okada YC, Romani GL, eds. Biomagnetism: Clinical Aspects. Amsterdam: Elsevier 1992. p. 585-8.
27. Jensen PD. Evaluation of iron overload. Br J Haematol 2004;124:697-711.
28. Fischer R. Liver iron susceptometry. In: Andrae W, Nowak H, editors. Magnetism In Medicine-A Handbook. Wiley-VHC, Berlin, 1998. p. 286-301.
29. Rouan MC, Marfil F, Mangoni P, Sechaud R, Humbert H, Maurer G. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001;755:203-13.
30. Aldudak B, Karabay BA, Noyan A, Ozel A, Anarat A, Sasmaz I, et al. Renal function in pediatric patients with β-thalassemia major. Pediatr Nephrol 2000;15:109-12.
31. Koliakos G, Papachristou F, Koussi A, Perifanis V, Tsatra I, Souliou E, et al. Urine biochemical markers of early renal dysfunction are associated with iron overload in β-thalassaemia. Clin Lab Haematol 2003;25:105-9.
32. Sumboonnanonda A, Malasit P, Tanphaichitr VS, Ong-ajyooth S, Sunthornchart S, Pattanakitsakul S, et al. Renal tubular function in β-thalassemia. Pediatr Nephrol 1998;12:280-3.
33. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006;107:3455-62.
34. Porter JB, Tanner MA, Pennell DJ, Eleftheriou P. Improved myocardial T2 in transfusion dependent anemias receiving ICL670 (Deferasirox). Blood 2005;106:[abstract 3600].
35. Wood JC, Otto-Duessel M, Gonzales I, Aguilar M, Nick H, Shimada H, et al. ICL670 removes cardiac iron in a gerbil model of iron overload. Blood 2005;106: [abstract 2695].
36. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-55.